Human Insulin Market 2032 eclipsing USD 46.59 billion

The Human Insulin market was valued at USD 24.88 billion in 2023 and is predicted to grow at a CAGR of 8.1%, with forecasts for 2032 eclipsing USD 46.59 billion. The market is driven by the rising prevalence of diabetes and obesity worldwide which can be attributed to the unhealthy lifestyles. For instance, over 30 million Americans (9.4% of the population) are diagnosed with diabetes in 2015, among which 23.1 million of individuals were diagnosed and remaining 7.2 million were undiagnosed. Also, diabetes is the 7th leading reason of the deaths in worldwide. Total cost of diagnosed diabetes in US for the year 2017 was around USD 327 billion. The introduction of the safety pen needles for accurate and safe delivery is another driving factor for the global human insulin market. The human insulin market is further propelled by regulations against needle stick injuries driving the demand for safe product developments, needle anxiety, and growing awareness of blood borne pathogen transmission, which leads to consumers buying new needles, further driving sales.

Insulin is a peptide hormone produced by the pancreas. It is considered to be the primary anabolic hormone which is responsible for the regulation of metabolism of carbohydrates, fats and protein by facilitating the absorption of glucose from the blood into liver, fat and skeletal muscle cells. Insulin promotes the conversion of small molecules in the blood into large molecules inside the cells. Low hormone levels in the blood promotes catabolism, which is the conversion of large molecules into smaller ones, especially of reserve body fat which may lead to numerous complications like loss of vision, unsteadiness of limbs, and obesity. A patient is prescribed different types of insulin based on many factors including their response to insulin, patient’s diet, alcohol intake and exercise. However, risk of skin infections at the catheter site, diabetic ketoacidosis, extremely high costs of drug and device and the hassle of checking blood glucose times per day may cause the consumer to opt out of insulin treatment which is expected to hamper the market. The insulin market is highly monopolistic with over 99% of the market captured by 3 companies which will restrain new entry into the market.

Request a Sample@

The global Human Insulin market has been segmented on the basis of product type, device type, and application. The research takes a closer look at prominent driving factors responsible for the 8.1% CAGR. The study also analyses the market share of each region, company and product. The report also presents constraints, opportunities, threats, challenges and Investment opportunities prevailing in the market.

Key Coverage

  • Region/country wide statistics with respect to year, regional prevalence
  • Estimation of market size
  • Types of Products
  • Upcoming products analyzed
  • Alternatives analyzed
  • Types of use analyzed
  • Status of ongoing developments
  • Analysis of regulatory framework/regulatory bodies
  • Demand and supply gap analysis
  • Competitor pricing strategy
  • Market share analysis
  • Strategic recommendations for new entrants/existing members/ key business segments
  • Market trends
  • Drivers, constraints, opportunities, threats, challenges, Investment opportunities
  • Competitive landscaping
  • Company profiling with strategies, financials and recent developments

Salient Features

  • According to the CDC, over a 100 million people in the US suffers from diabetes or had pre-diabetic conditions in 2018, which creates potential growth opportunities for insulin manufacturers
  • New insulin delivery products are constantly under development. Manufacturers are developing new-generation insulin pumps for higher compliance and integration with IT devices giving consumers a user interface
  • Over 8% of Indian adults suffer from diabetes, with more than 74 million Indians clinically diagnosed. Nearly 1 million Indians die due to diabetes every year. India is one of the largest demanding markets for insulin products
  • Hundreds of millions of dollars is spent by the major diabetic care companies on R&D of insulin products for maximizing efficiency and minimizing side effects. However, the three insulin giants have kept insulin production patent protected since 1923, restricting the manufacturing of generic insulin products
  • Mergers and acquisitions between major companies have boosted market growth. In 20th December 2013, Eli Lilly and Boehringer Ingelheim partnered up for the development and the commercialization of the drug Basaglar (Insulin Glargine)
  • Product development and launches have increased market prevalence. For instance, Novo Nordisk is developing a first once-weekly long-acting insulin for type I and type II diabetes, which is currently in phase 2 of the development stage. Eli Lilly is developing a long-acting insulin-Fc (LY3209590) for the same reasons

Companies Considered

Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.) are dominating players in the market and are the companies considered for this report.


  • The market is highly consolidated, with three companies namely, Eli Lilly, Sanofi and Novo Nordisk dominating 99% of the entire global insulin market According to the American Diabetes Association, the cost of insulin increased to $327 billion this year. With only three manufacturers controlling the market, there is no cheap alternative for the drug
  • On the basis of product, the drugs segment is expected to account for 87% of the global market in 2018 due to the need of consuming insulin drugs on a daily basis
  • On the basis of type, the pens segment is expected to account for 71% of the market share in 2018 and is also expected to be the fastest-growing segment during the forecast period as the pens are less invasive and minimal painful therapy in comparison with other therapies
  • By application, type II diabetes accounts for 95% of the market share as it is by far the most common diabetic case in adults. The prevalence of Type II diabetes mellitus has quadrupled during the last two decades due to the increased prevalence of obesity and the primary risk factor for type II diabetes
  • The Asia-Pacific market is estimated to be the fastest growing regional segment holding a CAGR of 9% during the forecast period, owing to growing diabetes and obesity prevalence in Asia Pacific, improved regulatory framework, strong distribution networks of global diabetic product manufacturers in the region, and rising public awareness related to benefits offered by human insulin in diabetes treatment.
  • North America is the chief revenue generator holding 53.6% of the market revenue share as US is the leading developed country with highest prevalence of diabetes which can be attributed to unhealthy lifestyle habits

Segments Covered

This report predicts revenue growth and CAGR at a global, regional & country level, and analyses the markets by studying the drivers, constraints, opportunities, threats, challenges, Investment opportunities, products, uses, trends, market shares in each of the sub-segments from 2023 to 2032. For the purpose of this study, I have segmented the global Human Insulin market report based on product type, drug type, device type, application, and region:

Product Type Outlook (Revenue, USD Million; 2023-2032)

  • Drugs
  • Delivery Devices

Drug Type Outlook (Revenue, USD Million; 2023-2032)

  • Insulin Analogs and Biosimilars
    • Long-Acting Biosimilars
    • Rapid-Acting Biosimilars
    • Premixed Biosimilars
  • Human Insulin Biologics
    • Short-Acting Biologics
    • Intermediate-Acting Biologics
    • Premixed Biologics

Device Type Outlook (Revenue, USD Million; 2023-2032)

  • Pens
    • Disposable Pens
    • Reusable Pens
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles
  • Syringes

Application Type Outlook (Revenue, USD Million; 2023-2032)

  • Type I Diabetes
  • Type II Diabetes

Regional Outlook (Revenue, USD Million; 2023-2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    • Brazil

Buy quantitative research Report at discounted price – USD 1500

You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333



About Us

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.

For Latest Update Follow Us:


Leave a Comment

Your email address will not be published. Required fields are marked *